Antibody composition-producing cell

Abstract

The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.

1 . A method of producing an antibody composition which comprises antibody molecules, wherein said method comprises culturing a mammalian cell that produces an antibody molecule, said mammalian cell having a decrease in, or an absence of, α1,6-fucosyltransferase activity,
 wherein said decrease in, or absence of, α1,6-fucosyltransferase activity results from deleting a gene encoding α1,6-fucosyltransferase, or from mutating said gene to reduce or eliminate the α1,6-fucosyltransferase activity. 
 
     
     
         2 . The method of  claim 1 , wherein said antibody molecule has an Fc region comprising two complex-type and/or hybrid-type N-glycoside-linked sugar chains bound to the Fc region, wherein said sugar chains comprise a reducing terminal which contains an N-acetylglucosamine, and wherein at least one of said sugar chains does not contain fucose bound to the 6-position of the N-acetylglucosamine in the reducing terminal of the sugar chain. 
     
     
         3 . The method of  claim 1 , wherein at least 80% of the antibody molecules produced by said cell are non-fucosylated antibody molecules. 
     
     
         4 . The method of  claim 3 , wherein the antibody molecules in said composition consist essentially of the non-fucosylated antibody molecules. 
     
     
         5 . The method of  claim 3 , wherein the antibody molecules in said composition consist of the non-fucosylated antibody molecules. 
     
     
         6 - 22 . (canceled) 
     
     
         23 . An antibody composition which comprises an antibody molecule, wherein said antibody molecule has an Fc region comprising two complex-type and/or hybrid-type N-glycoside-linked sugar chains bound to the Fc region, wherein said sugar chains comprise a reducing terminal which contains an N-acetylglucosamine, and wherein at least one of said sugar chains does not contain fucose bound to the 6-position of the N-acetylglucosamine in the reducing terminal of the sugar chain. 
     
     
         24 . A mammalian cell that has a decrease in, or an absence of, α1,6-fucosyltransferase activity, wherein said decrease in, or absence of, α1,6-fucosyltransferase activity is caused by deletion of a gene encoding α1,6-fucosyltransferase, or a mutation of said gene that reduces or eliminates the α1,6-fucosyltransferase activity. 
     
     
         25 . A method of treating a cancer, comprising administering the composition of  claim 23  to a subject in need thereof.